CEL-SCI Corporation (CVM)
NYSEAMERICAN: CVM · Real-Time Price · USD
1.150
0.00 (0.00%)
At close: Jul 16, 2026, 4:00 PM EDT
1.180
+0.030 (2.61%)
After-hours: Jul 16, 2026, 4:26 PM EDT
CEL-SCI Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
44
Market Cap
20.10M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | - | - | - |
| Sep 30, 2024 | - | - | - |
| Sep 30, 2023 | - | - | - |
| Sep 30, 2022 | - | - | - |
| Sep 30, 2021 | - | - | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCVM News
- 3 days ago - CEL-SCI to launch FDA registration-enabling Phase 3 Confirmatory study - TheFly
- 3 days ago - CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer - Business Wire
- 22 days ago - CEL-SCI, Saudi Amarox hold strategic agreement signing at BIO 2026 - TheFly
- 22 days ago - CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care - Business Wire
- 4 weeks ago - CEL-SCI Announces Closing of Offering - Business Wire
- 4 weeks ago - CEL-SCI highlights dual-track strategy for Multikine - TheFly
- 4 weeks ago - CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy - Business Wire
- 4 weeks ago - CEL-SCI Corporation Announces Pricing of Offering - Business Wire